

# Positioned to deliver sustained double-digit EPS<sup>1</sup> growth

1

## Sustainable & predictable markets

Driven by global megatrends, chronic care markets grow between 4-8% p.a.

We can sustainably outgrow our markets

2

## Leading market positions

#1 position in >60% of Group revenue

Consolidated industries with high barriers to entry

3

## Recurring revenue consumable products

>90% revenue from chronic care

c.900m units sold annually

4

## Strongest pipeline ever

Focus on fast growing market segments

8 new launches 2022-24

8 planned 2025-28

5

## Clear and deliverable medium-term targets

5-7% organic revenue growth<sup>2</sup>

24-26% operating profit margin<sup>3</sup>

Double-digit EPS growth<sup>1</sup>

6

## Driving shareholder value

Investing to grow with organic and bolt-on M&A investment

Progressive dividend policy

2.0x leverage target

## Our markets grow between 4-8%

### Advanced Wound Care (32% of sales)

c.6% market growth

Medium-term target: HSD growth

Cardiovascular disease & diabetes

### Ostomy Care (28% of sales)

c.4-5% market growth

Medium-term target: MSD growth

Bowel/bladder cancer & Crohn's disease

### Continence Care (22% of sales)

c.4% market growth

Medium-term target: MSD growth

Multiple Sclerosis & spinal cord injuries

### Infusion Care (18% of sales)

c.6-8% market growth

Medium-term target: HSD growth

Diabetes & Parkinson's Disease